"Pyridones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridine derivatives with one or more keto groups on the ring.
| Descriptor ID |
D011728
|
| MeSH Number(s) |
D03.383.725.791
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridones".
Below are MeSH descriptors whose meaning is more specific than "Pyridones".
This graph shows the total number of publications written about "Pyridones" by people in this website by year, and whether "Pyridones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 4 | 2 | 6 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 7 | 9 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 8 | 11 |
| 2020 | 5 | 5 | 10 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 5 | 5 |
| 2023 | 2 | 8 | 10 |
| 2024 | 7 | 9 | 16 |
| 2025 | 1 | 3 | 4 |
| 2026 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridones" by people in Profiles.
-
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Mol Cancer Ther. 2026 May 04; 25(5):844-859.
-
Dolutegravir developmental toxicity is mitigated by magnesium and folate in zebrafish embryos. Dis Model Mech. 2026 05 01; 19(5).
-
Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. J Int AIDS Soc. 2026 May; 29(5):e70108.
-
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial. Lancet HIV. 2026 Jun; 13(6):e367-e379.
-
Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis. BMC Pulm Med. 2026 Mar 23; 26(1).
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
-
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance. Pediatr Infect Dis J. 2026 Jul 01; 45(7):620-622.
-
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20?years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar; 162:108213.
-
Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis. Am J Kidney Dis. 2026 Mar; 87(3):313-323.
-
Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii. Diagn Microbiol Infect Dis. 2025 Nov; 113(3):116991.